LATEST NEWS
Final analysis reports a lack of overall survival benefit with datopotamab deruxtecan in HR+/HER2– breast cancer compared to chemotherapy
However, secondary endpoints of the TROPION-Breast01 continue to support a potential benefit of the antibody-drug conjugate in previously treated patients
Clinical benefits shown with pembrolizumab plus chemotherapy regardless bevacizumab use in advanced or recurrent cervical cancer
Findings are from an exploratory subgroup analysis of the KEYNOTE-826
A little does not go a long way to treating cancer: updated ESMO study results cause concern about stalling progress in access to medicines
The updated Antineoplastic Medicine Survey (ANMS) dataset shows that essential therapies remain out of reach for patients in most low and lower middle-income countries despite international efforts
Neoadjuvant pembrolizumab plus chemotherapy increases pathological complete response in high-risk early breast cancer
Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer
Tiragolumab plus atezolizumab failed to improve overall survival in advanced non-squamous NSCLC
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
An oncolytic adenovirus shows promise in inducing immune response in prostate cancer
Early-phase data suggest that intratumour injections of ORCA-010 may convert cold tumours into immunogenic ones
COLUMNS
Innovation means progress for all people with cancer
Effectiveness, applicability and accessibility measure the value of novel technologies and therapies in oncology
Redispensing cancer medicines means caring for the environment
Some initiatives show that collection and distribution of unused medicines can help tackle drug waste, with a potential impact on emissions associated to oncology therapies
The expanding toolbox for immuno-oncology
Novel treatment approaches show encouraging early results in solid tumours, but ways to boost precision immunotherapy are needed
OPINIONS
ctDNA and beyond to serve immunotherapy
Umberto Malapelle
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Christian Blank
Preventing the rise in obesity-related cancers in Asia
Elick Narayan
Translating cancer genome insights into practical clinical tools
Elli Papaemmanuil
Innovation is leading to a comprehensive ‘map’ of tumours
Joakim Lundeberg
OPINIONS
ctDNA and beyond to serve immunotherapy
Umberto Malapelle
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Christian Blank
Preventing the rise in obesity-related cancers in Asia
Elick Narayan
Translating cancer genome insights into practical clinical tools
Elli Papaemmanuil
Innovation is leading to a comprehensive ‘map’ of tumours
Joakim Lundeberg